Key Takeaways
- In the OPUS-1 Phase 3 trial, VAX-31 met noninferiority on all 28 serotypes it shares with PCV20 and PCV21 in adults 50 and older, and superiority on all four of its unique comparisons.
- Vaxcyte estimates VAX-31 would cover about 95% of invasive pneumococcal disease in US adults 50 and older, but a license application is not expected until the first half of 2028.
- CDC data show only 37% of adults aged 50 to 64 with a risk-based recommendation and 70% of adults 65 and older had received a pneumococcal vaccine in 2022.
- In US nursing homes, 2024–25 flu vaccination reached 61.3% of residents and just 42.1% of health care personnel, a signal of how thin vaccine delivery capacity is in long-term care.
Pneumococcal vaccines have been locked in a valency race for a decade, each new conjugate adding serotypes to stay ahead of the strains that replace the ones already covered. Vaxcyte's VAX-31 now has pivotal data showing it can carry 31 serotypes without giving up immune response against the vaccines already on the market. That is a real manufacturing and immunology achievement. But the population the vaccine is built for, adults 50 and older, is one where existing vaccines already reach too few people, and the settings with the highest risk struggle to deliver even routine shots. Broader coverage on the label only becomes broader protection if the shot gets into arms.
A Pivotal Readout That Cleared Every Primary Bar
Vaxcyte reported topline OPUS-1 results on October 5. The randomized, double-blind trial dosed 4,047 participants at about 30 US sites: 3,572 adults aged 50 and older, randomized one to one to one to VAX-31, PCV20 or PCV21, and 475 adults aged 18 to 49. In the older cohort, all 28 serotypes VAX-31 shares with one or both comparators met the prespecified noninferiority criterion, and the three serotypes unique to VAX-31, plus cross-reactive serotype 20B, met the stricter superiority criterion. The younger cohort met its immunobridging endpoint against adults aged 50 to 64.
The head-to-head detail matters for positioning. Against PCV20, VAX-31 was noninferior on 20 of 20 shared serotypes. Against PCV21, it was noninferior on 17 of 19 under the primary threshold; serotypes 3 and 12F fell short of that bar but cleared the historical threshold used as a prespecified key secondary endpoint. The company said reactions were generally mild to moderate, with no vaccine-related serious adverse events and no discontinuations for adverse events. CEO Grant Pickering called the results the clinical cornerstone for a planned license application, which Vaxcyte expects to submit in the first half of 2028, after two further Phase 3 studies read out in the first half of 2027.
Vaxcyte's own estimate is that VAX-31 would cover roughly 95% of invasive pneumococcal disease and about 88% of pneumococcal pneumonia in US adults 50 and older, an increment of 13% to 36% over current adult vaccines for invasive disease. Those are company projections from serotype distribution, not efficacy results, and the FDA will judge the vaccine on immunogenicity and safety. Still, the serotype math explains why the market cares: CDC surveillance cited in the 2025 ACIP recommendation report found PCV20 serotypes accounted for 56% of invasive disease in adults aged 50 to 64, against 83% for PCV21.
The Coverage Gap Sits Upstream of the Vaccine
That same report is where the harder problem shows up. ACIP voted in October 2024 to recommend a single conjugate dose for every vaccine-naive adult aged 50 and older, lowering the age threshold from 65. The rationale was burden: in 2022, invasive pneumococcal disease incidence was 13.2 per 100,000 among adults aged 50 to 64 and 17.2 among those 65 and older, with death rates of 1.8 and 2.7 per 100,000. About 90% of adults aged 50 to 64 with invasive disease had at least one risk condition, the group that was already supposed to be vaccinated.
Most of them were not. In 2022 survey data, only 37% of adults aged 50 to 64 with a risk-based recommendation had received a pneumococcal vaccine, and coverage among adults 65 and older, who have had an age-based recommendation for years, was 70%. The report also notes persistent racial disparities, with higher disease rates among Black and American Indian or Alaska Native adults and differences in vaccination coverage. A vaccine that adds serotypes improves protection for the people who receive it. It does nothing for the majority of at-risk middle-aged adults who never get any pneumococcal shot, and that group is where the expanded recommendation is meant to land.
Long-Term Care Shows How Thin Delivery Can Be
The highest-risk older adults often live in nursing homes, and federal data show how unevenly those facilities deliver vaccines. A CDC analysis published in April covering 13,299 nursing homes, about 1.2 million residents and 2.1 million health care personnel, found influenza vaccination reached 61.3% of residents and 42.1% of staff in the 2024–25 season. Staff coverage fell from 45.4% the season before and sat far below the 80.7% reported for personnel in acute care hospitals. Resident coverage ranged from 33.0% to 80.6% across states and was lowest, at 58.5%, in for-profit facilities.
Flu is not pneumococcal disease, and the two programs are tracked differently. But the flu data measure the same machinery a new pneumococcal vaccine will depend on: someone has to check each resident's history, document consent, administer the dose and record it, and staff coverage that low suggests that machinery is stretched. The CDC authors also note that staff vaccination can reduce absenteeism and support staffing stability. For a vaccine maker, these facilities are where a broader serotype profile should matter most, and where the operational barrier to uptake is highest.
What Life Sciences Leaders Should Do Now
- Plan the launch around the coverage gap, not only the serotypes: With only 37% of at-risk adults aged 50 to 64 vaccinated, the larger commercial opportunity is reaching unvaccinated adults, not switching those already protected.
- Build the real-world evidence case early: Projected disease coverage is a serotype estimate. Payers and guideline committees will want surveillance and outcomes data on pneumonia and hospitalization once the vaccine is in use.
- Prepare for the serotype 3 and 12F questions: Results against PCV21 on those two serotypes will shape how clinicians and ACIP weigh the vaccines, so medical teams should have a clear, data-led answer ready.
- Treat long-term care as its own channel: Nursing homes need documentation support, standing orders and staff capacity to vaccinate residents, and their staff coverage numbers show the gap is operational, not clinical.
- Target the disparities explicitly: Higher disease rates and lower coverage among Black and American Indian or Alaska Native adults make community partnerships part of launch strategy, not an afterthought.
- Use the runway before 2028: With a license application not expected until the first half of 2028, there is time to work with health systems and plans on the uptake infrastructure the vaccine will need.
VAX-31 has done what a next-generation conjugate vaccine needs to do in a pivotal trial. Whether it changes the burden of pneumococcal disease in older adults will be decided less by the 31 serotypes in the vial than by how many eligible adults, in clinics and nursing homes, actually receive one.
